|
|
 |
|
Viewing report
|
|
|
|
Prostate Cancer Vaccines and Therapeutic Antibodies: Pipeline - 2011
BioPharm Reports (VennBio Ltd.), Feb 2011, Pages: 95
The prostate cancer immunotherapy pipeline is showing rapid development. Currently, there are 30 candidates in the pipeline (16 vaccines and 14 therapeutic antibodies), and one prostate cancer vaccine (Provenge®) has recently been approved by the FDA.
First-line treatments for prostate cancer are largely based on anti-androgen drugs, or pituitary down-regulators. Other treatments include surgery, radiotherapy and chemotherapy. Resistance is commonly seen in the case of androgen-targeting drugs. Other therapies such as surgery and radiotherapy may be effective, but present increased risk. These treatment limitations have prompted efforts to develop safer, targeted therapies.
In April 2010, Dendreon Inc. received FDA approval for its vaccine, Provenge® – an autologous cellular immunotherapy developed for metastatic prostate cancer. This vaccine is based on the use of patients' own peripheral blood mononuclear cells, following prior treatment with a Prostate Acid Phosphatase/Granulocyte-Macrophage Colony-Stimulating Factor (PAP/GM-CSF) fusion protein. PAP is a commonly expressed prostate cancer antigen.
The development of new candidate vaccines and therapeutic antibodies to target prostate cancer, is showing rapid progress. There are 30 candidates in the pipeline (16 prostate cancer vaccines and 14 prostate cancer-targeting antibodies), and one FDA-approved prostate cancer vaccine (Provenge®). Of these candidates, 19 are at Phases II and III (nine vaccines and 10 antibodies) and eight are at Phase I.
These vaccines and antibodies are targeting more than fifteen different prostate cancer-associated antigens or other prostate cancer-associated proteins, and are being taken forward by 25 companies: 20 small and medium sized enterprises, and five multinational pharmaceutical companies.
This report provides a comprehensive update on the prostate cancer immunotherapy pipeline, and includes summary pre-clinical and clinical findings (pre-clinical to Phase III) on the candidate vaccines and antibodies presented.
This report provides:
- A comprehensive update on the prostate cancer vaccine and therapeutic antibody pipeline;
- Summary pre-clinical and clinical findings (where published) for all candidate vaccines and antibodies presented;
- Descriptions of vaccine-targeting mechanisms (antigens and targets);
- Details of development companies.
|
|
|
|
